Market Research Industry Today
Hypoparathyroidism Market Growth Anticipated by 2032 | Major Players: Takeda, Ascendis Pharma, EnteraBio, Bridgebio, Calcilytix Therapeutics
In the market landscape of Hypoparathyroidism, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled “Hypoparathyroidism Market Insights, Epidemiology and Market Forecast, 2032” from DelveInsight.
Increasing cases of Hypoparathyroidism in various regions lead to increased demand for advanced diagnostic and treatment in the Hypoparathyroidism market, which in turn contribute to the growth of the market.
The report sheds light on Hypoparathyroidism current treatment practices, upcoming drugs in the Hypoparathyroidism pipeline, market shares of individual therapies, and the anticipated trajectory of the Hypoparathyroidism market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).
Driving Forces Behind the Hypoparathyroidism Market Growth
The market is expected to grow by factors like an increase in the patient pool, and expected entry of emerging therapies.
Discover the Anticipated Evolution and Growth of the Market @ Hypoparathyroidism Therapeutics Market Forecast
Therapeutic Advancements and Emerging Treatments:
- Hypoparathyroidism Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Takeda, Ascendis Pharma, EnteraBio, Bridgebio, Calcilytix Therapeutics, and others, are actively engaged in developing novel drugs for potential market entry.
- Hypoparathyroidism Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Hypoparathyroidism. Therapies such as TransCon PTH, EB612, Encaleret, and others are driving the Hypoparathyroidism market.
Hypoparathyroidism Market Dynamics
In November 2021, Ascendis Pharma announced top-line results from Week 84 of the Company’s Phase II PaTH Trial. The week 84 data showed that subjects treated with TransCon PTH had both mean serum calcium levels and urinary calcium excretion that remained stable and in the normal range and that most subjects (93%) continued to be free from taking active vitamin D and were taking < 600 mg/day of calcium supplements. TransCon platform could prove to be a major value driver for the hypoparathyroidism market, making TransCon PTH a competitor of Natpara. Apart from TransCon PTH, EB612 has also continued to make good progress for hypoparathyroidism. It has been observed that oral PTH is effectively delivered into the bloodstream and activates PTH-dependent biological pathways inadequately activated in patients with hypoparathyroidism. As per our analysis, TransCon PTH was found to be the most promising upcoming drug, followed by EB612 (PTH 1-34) and Encaleret. The analysis is based on different parameters such as efficacy, safety, ROA, and various other factors, further explained in detail in the attribute analysis.
Hypoparathyroidism Treatment Market
The present Hypoparathyroidism market is looking forward to the introduction of new products such as TransCon PTH by Ascendis Pharma, EB612 by EnteraBio, and Encaleret by Bridgebio/Calcilytix Therapeutics.
TransCon PTH is a potential prodrug of parathyroid hormone (PTH) designed for once-daily hormone replacement therapy, aiming to restore normal PTH levels continuously throughout the day. However, in April 2023, Ascendis Pharma received notification from the FDA regarding deficiencies in their New Drug Application (NDA) for TransCon PTH in treating hypoparathyroidism, which is currently hindering further discussions about labeling and post-marketing requirements/commitments.
EB612, an oral form of human parathyroid hormone (1-34) (PTH), plays a crucial role in regulating calcium and phosphorus levels in the blood. EnteraBio's efforts for this drug have gained approval for Orphan Drug designation from the FDA in April 2014 for hypoparathyroidism. Additionally, they received positive assessments from the EMA in May 2016 and published Phase IIa study results in February 2021.
Encaleret, an investigational small molecule antagonist targeting the calcium-sensing receptor (CaSR), is being studied for calcium homeostasis disorders, including autosomal dominant hypocalcemia type 1 (ADH1). Bridgebio/Calcilytix Therapeutics obtained orphan drug designations for Encaleret from the FDA to address autosomal dominant hypocalcemia, including ADH type 1 and ADH type 2. Furthermore, the FDA granted Fast Track designation for encaleret in June 2021 for treating autosomal dominant hypocalcemia (ADH1). Currently, the drug is in the Phase-III stage of clinical development.
Hypoparathyroidism Market Report Features
Geography Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Study Period: 2019-2032
Market Size: ~USD 250 million in 2022
Key Companies: Takeda, Ascendis Pharma, EnteraBio, Bridgebio, Calcilytix Therapeutics, and others.
Leading Hypoparathyroidism Companies and Emerging Drugs: Pioneering companies such as Takeda, Ascendis Pharma, EnteraBio, Bridgebio, Calcilytix Therapeutics, among others, are actively developing novel drugs for potential entry into the Hypoparathyroidism market.
Hypoparathyroidism Therapeutic Landscape: Key therapies identified for Hypoparathyroidism treatment include TransCon PTH, EB612, Encaleret, and more.
Hypoparathyroidism Overview:
Hypoparathyroidism is identified by low levels of calcium (hypocalcemia) and high levels of phosphorus (hyperphosphatemia) resulting from a deficiency in the secretion or function of parathyroid hormone (PTH). This condition may manifest as part of an autoimmune disorder affecting multiple glands or as a congenital anomaly, as seen in syndromes such as autosomal dominant DiGeorge or hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromes.
The primary cause of this condition often stems from injury or complete removal of all four parathyroid glands, which can inadvertently occur during thyroid surgery. Some individuals are born without these glands, while in other cases, the glands may not function adequately for reasons unknown.
Symptoms of hypocalcemia usually involve tingling around the mouth (perioral numbness), abnormal sensations (paresthesia), cognitive impairment, muscle weakness, and spasms in the hands and feet (carpopedal spasms). Severe complications, including irregular heartbeats, spasms in the larynx, tetany, and seizures, can also arise.
Treatment involves tailored calcium supplementation and critical vitamin D administration. Recombinant human PTH exists as a therapeutic option, although it's often considered a secondary choice due to its cost and because the long-term safety profile hasn't been entirely established.
Hypoparathyroidism is a condition characterized by low levels of parathyroid hormone (PTH), leading to decreased levels of calcium in the blood and increased levels of phosphorus. Symptoms of hypoparathyroidism can vary in severity and may include:
Tingling and numbness: Especially around the lips, fingers, and toes (known as perioral numbness).
Muscle cramps and spasms: Carpopedal spasms affecting the hands and feet are common, causing involuntary muscle contractions.
Fatigue and weakness: Generalized weakness or muscle fatigue that may affect daily activities.
Abnormal sensations: Such as tingling or a "pins and needles" sensation in the extremities (paresthesia).
Muscle stiffness: Cramps or muscle stiffness that can affect movement and flexibility.
Mental symptoms: Cognitive impairments, including memory problems, difficulty concentrating, and confusion.
Abdominal symptoms: Nausea, vomiting, and abdominal pain can occur in some cases.
Dry skin and hair: Due to changes in calcium levels, skin and hair may become dry and brittle.
Irregular heartbeats: Severe cases can lead to heart palpitations or irregular heart rhythms.
Seizures: In extreme cases, low calcium levels may trigger seizures or convulsions.
Key Facts Hypoparathyroidism Market Report:
- Key players such as Ascendis Pharma, EnteraBio, and Bridgebio/Calcilytix Therapeutics are investigatingits candidates for Hypoparathyroidism.
- More than 80% of chronic hypoPTH cases are caused by the accidental removal or damage to the parathyroid glands during surgery on the front part of the neck. Thus, with the rising cases of hypoPTH, the market of treatment is expected to upsurge in the forecast period.
- Among the 7MM, US accounts for the largest market size of Hypoparathyroidism, in comparison to EU4and the UK (United Kingdom, Spain, Italy, France, Spain) and Japan.
Hypoparathyroidism Epidemiology Segmentation:
“HypoPTH happens when 1 or more of parathyroid glands are not active enough. According to NORD there areapproximately 70,000 people with hypoPTH in the United States. It can affect individuals of any age.”
- The total prevalent population of hypoparathyroidism in the 7MM was ~284,000 in 2022 and is expected to increase by 2032.
- In 2022, there were ~22,500 prevalent cases of Hypoparathyroidism in Japan. These cases are expected to increase during the forecast period (2023-2032).
- As far as cause-specific diagnosed prevalence isconcerned, surgery accounted for ~11,000cases inJapan, in 2022.
- Among EU4 and the UK, the UK had thehighestprevalent population of hypoparathyroidism with~35,000 cases, followed by GermanyandFrancein2022. On the other hand, Spainhad the lowestprevalent population of hypoparathyroidism.
The Hypoparathyroidism market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
• Total Prevalence of Hypoparathyroidism
• Prevalent Cases of Hypoparathyroidism by severity
• Gender-specific Prevalence of Hypoparathyroidism
• Type-specific Prevalence of Hypoparathyroidism
• Age-specific Prevalence of Hypoparathyroidism
• Diagnosed Cases of Hypoparathyroidism
DelveInsight's comprehensive report provides a thorough exploration of the Hypoparathyroidism market, covering key Hypoparathyroidism players, emerging Hypoparathyroidism therapies, treatment dynamics, and market challenges.
For in-depth insights, access the full report @ Hypoparathyroidism Market Outlook 2032
DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Hypoparathyroidism market landscape.
- Gain Competitive Edge in Indication Market : Understand the current landscape of the Hypoparathyroidism market, including the competitive environment, key companies developing drugs for Hypoparathyroidism , and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
- Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing tretment practices can helps in identifying gaps and opportunities within the Hypoparathyroidism market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Hypoparathyroidism. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
- Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
- Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Hypoparathyroidism market with clarity and purpose.
Related Reports:
Hypoparathyroidism Epidemiology Forecast
Hypoparathyroidism Epidemiology Forecast report delivers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Hypoparathyroidism Pipeline Insight
Hypoparathyroidism Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Hypoparathyroidism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Healthcare Consulting and Market Research Services by DelveInsight
Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European biosimilar landscape. Download Pharma Go-to-Market Case Study.
Trending Reports by DelveInsight
Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market
Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market
Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market
Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market
Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market
Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market
Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market
Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market
Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market
Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market
Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market
Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market
Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market
Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market
Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market
Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market
About DelveInsight:
DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.
Connect with DelveInsight:
Contact Us:
Kritika Rehani
Team Lead, Marketing
krehani@delveinsight.com
+91-9650213330
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
